Bharatham Kavitha, Bharatham Nagakumar, Kwon Yong Jung, Lee Keun Woo
Division of Applied Life Science (BK21 Program), Environmental Biotechnology National Core Research Center, Gyeongsang National University, Jinju, 660-701, Korea.
J Comput Aided Mol Des. 2008 Dec;22(12):925-33. doi: 10.1007/s10822-008-9229-0. Epub 2008 Aug 7.
Allosteric inhibition of protein tyrosine phosphatase 1B (PTP1B), has paved a new path to design specific inhibitors for PTP1B, which is an important drug target for the treatment of type II diabetes and obesity. The PTP1B1-282-allosteric inhibitor complex crystal structure lacks alpha7 (287-298) and moreover there is no available 3D structure of PTP1B1-298 in open form. As the interaction between alpha7 and alpha6-alpha3 helices plays a crucial role in allosteric inhibition, alpha7 was modeled to the PTP1B1-282 in open form complexed with an allosteric inhibitor (compound-2) and a 5 ns MD simulation was performed to investigate the relative orientation of the alpha7-alpha6-alpha3 helices. The simulation conformational space was statistically sampled by clustering analyses. This approach was helpful to reveal certain clues on PTP1B allosteric inhibition. The simulation was also utilized in the generation of receptor based pharmacophore models to include the conformational flexibility of the protein-inhibitor complex. Three cluster representative structures of the highly populated clusters were selected for pharmacophore model generation. The three pharmacophore models were subsequently utilized for screening databases to retrieve molecules containing the features that complement the allosteric site. The retrieved hits were filtered based on certain drug-like properties and molecular docking simulations were performed in two different conformations of protein. Thus, performing MD simulation with alpha7 to investigate the changes at the allosteric site, then developing receptor based pharmacophore models and finally docking the retrieved hits into two distinct conformations will be a reliable methodology in identifying PTP1B allosteric inhibitors.
蛋白酪氨酸磷酸酶1B(PTP1B)的变构抑制为设计PTP1B的特异性抑制剂开辟了一条新途径,PTP1B是治疗II型糖尿病和肥胖症的重要药物靶点。PTP1B1 - 282 - 变构抑制剂复合物晶体结构缺少α7(287 - 298),而且没有开放形式的PTP1B1 - 298的可用三维结构。由于α7与α6 - α3螺旋之间的相互作用在变构抑制中起关键作用,因此将α7建模到与变构抑制剂(化合物 - 2)复合的开放形式的PTP1B1 - 282上,并进行了5纳秒的分子动力学(MD)模拟,以研究α7 - α6 - α3螺旋的相对取向。通过聚类分析对模拟构象空间进行统计采样。这种方法有助于揭示PTP1B变构抑制的某些线索。该模拟还用于生成基于受体的药效团模型,以纳入蛋白质 - 抑制剂复合物的构象灵活性。选择三个高度聚集簇的簇代表性结构用于药效团模型生成。随后利用这三个药效团模型筛选数据库,以检索包含与变构位点互补特征的分子。根据某些类药性质对检索到的命中物进行筛选,并在蛋白质的两种不同构象中进行分子对接模拟。因此,用α7进行分子动力学模拟以研究变构位点的变化,然后开发基于受体的药效团模型,最后将检索到的命中物对接至两种不同构象,将是鉴定PTP1B变构抑制剂的可靠方法。